This was a prospective, multicenter, open-label, randomized controlled trial. 77Seventy-seven patients of mild-to-moderate CAP with aspiration factors were enrolled and randomly assigned to receive moxifloxacin or levofloxacin plus metronidazole. A total of 23 patients (76.7%) in the moxifloxacin group achieved clinical cure and 15 (51.7%) in the levofloxacin plus metronidazole group (χ2=4.002，P
↧